Treatment for paraneoplastic neuropathies

Area of Science:

• Neurology
• Oncology
• Clinical Trials

Background:

• Peripheral nervous system involvement is common in non-nervous system tumors.
• Paraneoplastic neuropathies, immune-mediated conditions, are the most frequent paraneoplastic syndromes.
• These neuropathies are heterogeneous and require diverse therapeutic strategies.

Purpose of the Study:

• To systematically assess data from randomized controlled trials (RCTs) on treatments for paraneoplastic neuropathies.
• To evaluate the benefits and harms of interventions for these conditions.

Main Methods:

• Searched multiple databases (Cochrane, CENTRAL, MEDLINE, EMBASE, LILACS) for RCTs, quasi-RCTs, and controlled studies.
• Also searched for comparative cohort studies, case-control studies, and case series.
• Data extraction and adverse event collection were planned by independent reviewers.

Main Results:

• No RCTs or quasi-RCTs were identified for inclusion.
• Six non-randomized studies (54 participants) were included for discussion.
• Treatments focused on tumor management and immunomodulation, primarily intravenous immunoglobulin.

Conclusions:

• Currently, no RCTs or quasi-RCTs provide evidence-based guidance for treating paraneoplastic neuropathies.
• Existing evidence for immunomodulatory treatments (IVIg, plasma exchange, steroids, chemotherapy) is limited to case series, reports, or expert opinion (Class IV evidence).